| Literature DB >> 35284792 |
Fatma Sari Dogan1, Vehbi Ozaydin2.
Abstract
Objective: Anaphylaxis is an acute, life-threatening, systemic hypersensitivity reaction. It is usually triggered by drugs, foods, and insect stings. The primary objective of our study is to determine the factors affecting drug-induced anaphylaxis to contribute to early diagnosis and treatment in these patients.Entities:
Keywords: Adrenaline; Naranjo score; anaphylaxis; drug-induced anaphylaxis; emergency
Year: 2021 PMID: 35284792 PMCID: PMC8848485 DOI: 10.14744/nci.2021.56667
Source DB: PubMed Journal: North Clin Istanb ISSN: 2536-4553
Anaphylaxis diagnostic criteria
| 1. | If the allergen is unknown: |
| • Skin and mucosa findings AND | |
| • Respiratory symptoms OR | |
| • Hypotension OR | |
| • Organ failure (hypotonia, syncope, collapse, incontinence) | |
| 2. | The presence of 2 or more after encountering a possible allergen: |
| • Skin and mucosal findings (itching, rash, urticaria; tongue, soft palate, cheek, eyelid, or corneal swelling that may not be in 20% patients), | |
| • Respiratory symptoms (cough, wheezing, shortness of breath, change in voice) | |
| • Hypotension*, organ failure (syncope, collapse), | |
| • GIS symptoms (vomiting, cramp-like abdominal pain...) | |
| 3. | Rapidly developing hypotension after exposure to a known allergen |
*Hypotension: Systolic blood pressure <90 mmHg or <30% of that person’s baseline value.
Naranjo score
| Yes | No | Unknown or not examined | ||
|---|---|---|---|---|
| 1. | Are there clear reports that have previously reported this effect? | +1 | 0 | 0 |
| 2. | Has the adverse event developed after administration of the suspected drug? | +2 | –1 | 0 |
| 3. | Has the adverse effect begun to improve when medication is released or a special antidote is applied? | +1 | 0 | 0 |
| 4. | Did the adverse effect repeat when the drug was applied again? | +2 | –1 | 0 |
| 5. | Are there alternative reasons that may cause ımpact? | –1 | +2 | 0 |
| 6. | Did the effect reappear when placebo was given? | –1 | +1 | 0 |
| 7. | Is the drug detected at toxic concentrations in any body fluid? | +1 | 0 | 0 |
| 8. | Has the effect increased when the dose is increased, or is the effect decreased when it is decreased? | +1 | 0 | 0 |
| 9. | Is there a similar history of effect against a same or similar medication ın patient resume? | +1 | 0 | 0 |
| 10. | Has the adverse event been evidenced by any objective evidence? | +1 | 0 | 0 |
>9: Definite AE; 5–8: Probable AE; 1–4: Possible AE; 0: Doubtful AE.
Clinical findings and managements
| Variable | % (n=44) |
|---|---|
| Clinic findings | |
| Skin symptoms+Hypotension | 47.7 |
| Skin+Respiratory symptoms | 18.2 |
| Hypotension+Respiratory symptoms | 11.4 |
| Skin+Gastro-intestinal system symptoms | 11.4 |
| Hypotension+Skin+Respiratory symptoms | 6.8 |
| Hypotension | 2.3 |
| Respiratory symptoms | 2.3 |
| Management | |
| F+AH | 6.8 |
| F+AH+S+R | 54.5 |
| F+AH+S+R+A |
|
*F: IV fluid resuscitation; AH: Antihistamines; A: Adrenaline; R: Ranitidine.
Drugs that cause anaphylaxis
| Drugs | % (n=44) |
|---|---|
| Antibiotics | 36.4 |
| NSAID | 18.2 |
| Paracetamol | 13.6 |
| Proton-pump inhibitor | 11.4 |
| Multiple | 9.1 |
| Radiologic contrast | 4.5 |
| Unknown | 6.8 |
NSAID: Nonsteroidal anti-inflammatory drug.
Relationship between presence of clinical findings and adrenaline
| Clinic findings | n (%) | n (adrenalin+) | p |
|---|---|---|---|
| Skin symptoms | 37 (88.6) | 12 | 0.08 |
| Respiratory symptoms | 17 (38.6) | 16 |
|
| Cardiovascular symptoms | 30 (68.2) | 9 | 0.085 |
| Gastrointestinal system symptoms | 5 (11.4) | 0 | 0.139 |
Relationship between presence of clinical findings and steroid
| Clinic findings | n (%) | n (Steroid+) | p |
|---|---|---|---|
| Skin symptoms | 37 (84) | 34 | 1.00 |
| Respiratory symptoms | 17 (38.6) | 17 | 0.272 |
| Cardiovascular symptoms | 30 (68.2) | 30 | 0.027 |
| Gastrointestinal system symptoms | 5 (11.4) | 2 |
|